United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) - tablet, coated - 25 mg - hypertension (see boxed warning). hypersensitivity to reserpine; mental depression or history of mental depression (especially with suicidal tendencies); active peptic ulcer, ulcerative colitis; patients receiving electroconvulsive therapy. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease. anuria; hypersensitivity to this or other sulfonamide-derived drugs.

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - voriconazole - film-coated tablet - voriconazole 50 mg - antimycotics for systemic use

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - voriconazole - film-coated tablet - voriconazole 200 mg - antimycotics for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - febuxostat - film-coated tablet - febuxostat 80 mg - antigout preparations

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - febuxostat - film-coated tablet - febuxostat 120 mg - antigout preparations

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazapine tablets

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - voriconazole - treatment of:- invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei)- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder.   the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology ).  a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation.  the effectiveness of mirtazapine tablets in